Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection

Gerrit Jan Weverling, Peter Reiß(University of Amsterdam), Rui Proença(Portuguese Air Force Academy), Jens Lundgren(Centre of Excellence for Health, Immunity and Infections), Andrew N. Phillips(University College London), Juan Gonzales-Lahoz(Instituto de Salud Carlos III), Antonella d'Arminio Monforte(University of Milan), Amanda Mocroft(The Royal Free Hospital), Bruno Ledergerber(University Hospital of Zurich), Ole Kirk(University of Copenhagen)
The Lancet
April 1, 1999
10.1016/s0140-6736(99)03287-0
Cited by 223

Related Papers

Industrial enzyme applications
|Current Opinion in Biotechnology|2002|1.5k
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987